Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive–compulsive disorder
This study sought to investigate the efficacy of escitalopram at different dosages for the treatment of obsessive – compulsive disorder ( OCD ) . Thirty individuals were enrolled in a 16-week , open-label trial of escitalopram  and r and omly assigned to the 20 or 30 mg study arm . Study measures assessing OCD symptoms , anxiety , depression , and quality of life were administered at baseline and weeks 2 , 4 , 8 , 12 , and 16 . For the 23 study completers , pretreatment and posttreatment analyses revealed significant improvements ( P<0.05 ) on clinician-rated and self-rated measures of OCD symptoms , quality of life , anxiety , and depression . Approximately half of the sample ( n = 12 ) satisfied full medication response criteria and less than one-quarter ( n = 5 ) were partial medication responders . Intention-to-treat analyses showed similar improvements ( P<0.05 ) on all study measures . At study completion , a superior responder rate and more improvement on the Yale – Brown Obsessive Compulsive Scale ( P<0.05 ) was reported for those in the 30 versus 20 mg study arm . The difference between the two groups , however , disappeared when initial differences in baseline depression and anxiety scores were used as analysis covariates . These results suggest that the 30 mg ( vs. 20 mg ) dose of escitalopram may provide a superior reduction in OCD symptoms for those sufferers with comorbid depression and /or anxiety
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .